Archive for the ‘News’ Category

SGO And ACOG Announce Breast Cancer Fellowship Program For Gynecologic Oncologists

The Society of Gynecologic Oncologists (SGO) and the American College of Obstetricians and Gynecologists (ACOG) have jointly developed a breast disease fellowship training program for gynecologic oncologists. Supported by a grant of ,000 from ACOG, the program provides support for a gynecologic oncologist...
April 7th, 2009 | News | Read More

Researcher Cracks One Of The Mysteries Of Hodgkin’s Lymphoma

SHERBROOKE, QC — A professor at Université de Sherbrooke and his collaborators have succeeded in understanding how the cell responsible for Hodgkin’s lymphoma-a cancer of the lymph system-functions. In addition to answering a question that has baffled scientists for about a hundred years,...
April 7th, 2009 | News | Read More

Tests Could Find Ovarian Cancer Early, British Study Reports

LONDON — Doctors screening women for ovarian cancer were able to pick up the disease about two years earlier than normal, according to a British study published Wednesday. Scientists have long searched for a way to identify ovarian cancer early, which kills nearly 100,000 women worldwide every...
April 7th, 2009 | News | Read More

Proepithelin Encourages Cell Growth And Migration In Prostate Cancer

Researchers from Thomas Jefferson University have identified a protein that appears to play a significant role in the growth and migration of prostate cancer cells, especially androgen-independent prostate cancer cells. The study was published in the American Journal of Pathology. They also found that...
April 7th, 2009 | News | Read More

Gemin X Initiates Phase 2 Clinical Study Of Obatoclax In Combination With Standard Chemotherapy For First-Line Treatment Of Small Cell Lung Cancer

Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, announced the initiation of a Phase 2 clinical trial of its lead product candidate obatoclax (GX15-070) for the treatment of patients with extensive-stage small cell lung cancer (SCLC)....
April 7th, 2009 | News | Read More

CyberKnife Radiosurgery For Lung Cancer Sees Increased Interest And Continued Rapid Growth

Accuray Incorporated, a global leader in the field of radiosurgery, announced significant growth in CyberKnife lung cancer treatments in calendar year 2008. The number of lung cancer patients treated with CyberKnife radiosurgery in the United States grew 52 percent from calendar year 2007 to 2008 and...
April 7th, 2009 | News | Read More

Scientists Identify Key Genes In Colorectal And Liver Cancers: Study May Be Used For New Treatments

Researchers at the University of Minnesota have discovered key genes involved in colorectal and liver cancers, creating targets for the development of new drugs and therapies. Monday’s announcement is one piece of a large puzzle when it comes to the genetic origins of cancer. No single human gene...
April 7th, 2009 | News | Read More

Celator Pharmaceuticals Enrolls First Patient In Its Phase 2 Study Of CPX-351 In Acute Myeloid Leukemia In First Relapse

PRINCETON, N.J. — Celator Pharmaceuticals today announced that the first patient has been treated in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive salvage therapy in adult patients (up to 60 years old) with...
April 7th, 2009 | News | Read More

Gene Helps Protect Tumor Suppressor In Breast Cancer

Scientists at The University of Texas M. D. Anderson Cancer Center have discovered a gene that protects PTEN, a major tumor-suppressor that is reduced but rarely mutated in about half of all breast cancers. The gene Rak helps protect and regulate PTEN, which also is important in several other types...
April 7th, 2009 | News | Read More

GSK Seeks Approval Of Advanced Breast Cancer Drug For First-Line Treatment

GlaxoSmithKline on Wednesday applied for approval to market its breast cancer drug Tykerb in U.S. and Europe as a first-line treatment for women with advanced, hormone-sensitive breast cancer, the AP/Google.com reports. Tykerb, known as Tyverb in Europe, was approved two years ago in the U.S. Please...
April 6th, 2009 | News | Read More